Kar Madhabananda, Sultania Mahesh, Roy Souvick, Padhi Swatishree, Banerjee Birendranath
Department of Surgical Oncology, All India Institute of Medical Sciences, Bhubaneswar, Odisha 751019 India.
Molecular Stress and Stem Cell Biology Group, School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Bhubaneswar, Odisha 751024 India.
Indian J Surg Oncol. 2021 Apr;12(Suppl 1):128-133. doi: 10.1007/s13193-020-01217-0. Epub 2020 Oct 11.
The locoregional recurrence in oral cancer is not predicted by the histopathological parameters solely as the normal morphological looking cells harbor the genomic instability which acts as the potential tumor cells for recurrence in future. Therefore, there is an urgent need of the biomarker for prognostic stratification of patients with high risk of disease recurrence and appropriate management. Eighty oral squamous cell carcinoma (OSCC) patients were included in the study during the period 2012 to 2014 at Apollo Hospitals and Kalinga Institute of Medical sciences, Bhubaneswar. OSCC tissue samples were collected at the time of surgical excision, and immunohistochemistry (IHC) was performed to check the expression of -catenin in cut margin (CM) and tumor. Statistical analysis was carried out using SPSS based on clinical and pathological records. It was observed that among 80 patients, 33.75% (27 patients) developed recurrence. The recurrence rate was low for 6 out of 27 patients (22.2%) where -catenin is positive in tumor and negative in cut margin, while it was quite high in 21 out of 27 (77.8%) when marker is negative in tumor but positive in cut margin (CM). The odds of recurrence among patients having high levels of 𝛽-catenin in CM was 3.6 times higher than the odds of recurrence among patients having lower levels of 𝛽-catenin in CM ( < 0.017). In conclusion, this study highlighted that 𝛽-catenin can be included as a prognostic molecular marker, along with routine histopathological study to influence therapeutic decisions and appropriate management of disease.
口腔癌的局部区域复发不能仅通过组织病理学参数来预测，因为看似形态正常的细胞存在基因组不稳定性，这使其成为未来复发的潜在肿瘤细胞。因此，迫切需要一种生物标志物，用于对疾病复发风险高的患者进行预后分层并进行适当管理。2012年至2014年期间，阿波罗医院和布巴内斯瓦尔的卡林加医学科学研究所纳入了80例口腔鳞状细胞癌（OSCC）患者。在手术切除时收集OSCC组织样本，并进行免疫组织化学（IHC）检查β-连环蛋白在切缘（CM）和肿瘤中的表达。基于临床和病理记录，使用SPSS进行统计分析。观察到在80例患者中，33.75%（27例）出现复发。在27例患者中有6例（22.2%）复发率较低，其中肿瘤中β-连环蛋白呈阳性而切缘呈阴性，而当标志物在肿瘤中呈阴性但在切缘（CM）中呈阳性时，27例中有21例（77.8%）复发率相当高。切缘中β-连环蛋白水平高的患者复发几率比切缘中β-连环蛋白水平低的患者复发几率高3.6倍（P＜0.017）。总之，本研究强调β-连环蛋白可作为一种预后分子标志物，与常规组织病理学研究一起，以影响治疗决策和疾病的适当管理。
